I-Mab Reports Third Quarter 2024 Results

Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy data On track to dose first patient in randomized Phase 2 study ofuliledlimab in first-line mNSCLC in 1H 2025

Home Previous 59 60 61 62 63 64 65 Next Tail

10 Items Per Page (Page 62 / 136) Total 1358 Items

©copyright 2009-2020 Bot Ai Daily      Contact Us   SiteMap